Pfizer Says COVID-19 Vaccine Protection Lasts at Least 6 Months.
Pfizer and BioNTech announced that their ongoing
Phase 3 clinical vaccine trial confirms protection
for at least six months after the second dose.
The vaccine was also shown to be effective
in protecting against the B.1.351 variant,
which originated in South Africa.
The Pfizer/BioNTech vaccine remains
more than 91% effective against
being infected with any symptoms. .
These data confirm the
favorable efficacy and safety
profile of our vaccine.., Pfizer chairman and CEO Albert Bourla, via statement.
... and position us to submit a Biologics License Application (BLA)
to the U.S. FDA, Pfizer chairman and CEO Albert Bourla, via statement.
A BLA would put the vaccine, which is
currently under emergency use authorization,
in the running for full approval